Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 109; no. 10; pp. 3368 - 3372
Main Authors Zahr, Rima S., Rashkin, Sara R., Ruiz, Maria Armila, Elsherif, Laila, Ren, Guohui, Salas, Guadalupe, Ataga, Kenneth I., Gordeuk, Victor R., Lebensburger, Jeffrey, Zhang, Xu, Saraf, Santosh L.
Format Journal Article
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.10.2024
Ferrata Storti Foundation
Subjects
Adult
Anemia, Sickle Cell - blood
Anemia, Sickle Cell - metabolism
Anemia, Sickle Cell - pathology
Biomarkers
Disease Progression
Female
Humans
Kidney Diseases - etiology
Kidney Diseases - metabolism
Letter to the Editor
Male
Receptors, Urokinase Plasminogen Activator - blood
Receptors, Urokinase Plasminogen Activator - metabolism
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ObjectType-Feature-3
content type line 23
Disclosures
RSZ received research funding from the NIH/NHLBI K23HL157554. KIA has served on advisory boards for Novartis, Global Blood Therapeutics, Novo Nordisk, Roche and Forma Therapeutics. VRG has served as a consultant for Global Blood Therapeutics and Vifor Fresnius Medical Care Renal Pharma. JL discloses consultancy for Novartis, Agios and Forma Therapeutics for studies unrelated to this manuscript. SLS has served on advisory boards and as a consultant for Global Blood Therapeutics, Novartis, Agios, ORIC and Forma Therapeutics. All other authors have no conflicst of interest to disclose.
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2023.284920